Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 1999

View Archived Issues

BioStratum completes equity financing; updates research goals

Amarillo begins phase III trial of interferon alfa for Sjogren's syndrome

Results from phase III study of appendicitis diagnostic reported

Isis and Elan sign antisense agreement

Spotlight on MMP inhibitors in development for cancer

Peptidomimetic inhibitors of cellular Ras protein processing developed at Merck

Epicyte awarded SBIR and DARPA grants

Roche describes preparation and use of cell adhesion inhibitors for chronic inflammatory disorders

Serotonergic agents for depression under study at BASF

Production method and structure of all-trans-retinol metabolite disclosed by WARF

Orquest's bone substitute product approved in E.C.

HMR continues to focus R&D resources in the area of Na+/H+ exchange inhibitors

Novel macrolide antitumor agent in early clinical trials at Wyeth-Ayerst

Preclinical studies indicate potential of MMP inhibitor in brain and prostate cancers

4'-Thio-ara-C selected as potential clinical candidate at Southern Research Institute

AEterna presents evidence of clinical efficacy of lead MMP inhibitor at AACR meeting

News from AACR: orally active cemadotin analogue from BASF heads for clinic

Angiogenic molecules emerge as an important therapeutic target in cancer

Anti-VEGF aptamer is a potent inhibitor of tumor angiogenesis

Controlled-release formulation of paclitaxel endowed with superior in vivo antitumor activity

Once-weekly administration of topoisomerase II inhibitor is associated with reduced toxicity

Orally active MDR-reversing agent in phase I presented at AACR by Janssen

NIH investigates next-generation cancer immunotherapeutic

CL-387785: covalent, irreversible inhibitor of EGF and related receptor tyrosine kinases

Colazide receives pricing approval in Sweden

Farnesyltransferase inhibitors especially effective in combination with other chemotherapeutic drugs

Substituted purines and pyrimidines as inhibitors of cyclin-dependent kinases

E.U.-wide approval obtained for Regranex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...